World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
123
Citations
76024
World Ranking
3286
National Ranking
1810

Overview

Jeffrey S. Ross is affiliated with Foundation Medicine in the United States. Their research is primarily focused on cancer genomics, diagnostics, and treatment. The body of work covers several key areas within medicine and molecular biology, with a strong emphasis on oncology and related subfields.

Their main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these fields, subfields prominently represented in their publications are:

  • Surgery
  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Molecular Biology

The primary topics of research include:

  • Cancer Genomics and Diagnostics
  • Bladder and Urothelial Cancer Treatments
  • Cancer Immunotherapy and Biomarkers
  • Urinary and Genital Oncology Studies
  • Prostate Cancer Treatment and Research
  • Genetic factors in colorectal cancer
  • Lung Cancer Treatments and Mutations

Jeffrey S. Ross has contributed to a number of research papers, some of which are:

  • Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms (2021, Clinical Cancer Research)
  • Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer (2020, European Urology)
  • Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity (2020, JCO Precision Oncology)
  • Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma (2022, Nature Communications)
  • Clinicopathologic Characteristics of BRG1-Deficient NSCLC (2020, Journal of Thoracic Oncology)

Their frequent co-authors include:

  • Richard S.P. Huang
  • Andrea Necchi
  • Natalie Danziger
  • Dean C. Pavlick
  • Douglas I. Lin

Jeffrey S. Ross has published extensively in several prominent scientific venues. The most common journals for their work are:

  • Journal of Clinical Oncology
  • The Oncologist
  • Annals of Oncology
  • Cancer Research
  • JCO Precision Oncology

Best Publications

  • Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

    Zachary R. Chalmers;Caitlin F. Connelly;David Fabrizio

  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

    Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim

  • Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

    Garrett M Frampton;Alex Fichtenholtz;Geoff A Otto;Kai Wang

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

    Jeffrey S. Ross;Jonathan A. Fletcher

  • The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

    Jeffrey S. Ross;Elzbieta A. Slodkowska;W. Fraser Symmans;Lajos Pusztai

  • Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

    Doron Lipson;Marzia Capelletti;Roman Yelensky;Geoff Otto

  • HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

    Michael F. Press;Leslie Bernstein;Patricia A. Thomas;Lorraine F. Meisner

  • The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

    Jeffrey S. Ross;Jeffrey S. Ross;Jonathan A. Fletcher;Gerald P. Linette;Gerald P. Linette;James Stec

  • Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

    Garrett M. Frampton;Siraj M. Ali;Mark Rosenzweig;Juliann Chmielecki

  • Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer

    Rinath Jeselsohn;Roman Yelensky;Gilles Buchwalter;Gilles Buchwalter;Garrett Frampton

  • Correlation of Primary Tumor Prostate-Specific Membrane Antigen Expression with Disease Recurrence in Prostate Cancer

    Jeffrey S. Ross;Christine E. Sheehan;Hugh A. G. Fisher;Ronald P. Kaufman

  • Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

    Luca Gianni;Milvia Zambetti;Kim Clark;Joffre Baker

  • Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

    Jason K. Sicklick;Shumei Kato;Ryosuke Okamura;Maria Schwaederle

  • Lumbar degenerative disk disease.

    Michael T. Modic;Jeffrey S. Ross

  • Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.

    Thomas Wiesner;Jie He;Roman Yelensky;Rosaura Esteve-Puig

  • Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study

    Andrea Necchi;Andrea Anichini;Daniele Raggi;Alberto Briganti

  • Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

    Alexander Drilon;Lu Wang;Adnan Hasanovic;Yoshiyuki Suehara

  • Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets

    Justin M. Balko;Jennifer M. Giltnane;Kai Wang;Luis J. Schwarz

  • Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

    Roman Rouzier;Radhika Rajan;Peter Wagner;Kenneth R. Hess

Frequent Co-Authors

Siraj M. Ali
Siraj M. Ali Foundation Medicine
Philip J. Stephens
Philip J. Stephens Foundation Medicine
Garrett M. Frampton
Garrett M. Frampton Foundation Medicine
Lajos Pusztai
Lajos Pusztai Yale University
Sai-Hong Ignatius Ou
Sai-Hong Ignatius Ou University of California, Irvine
Shridar Ganesan
Shridar Ganesan Rutgers, The State University of New Jersey
W. Fraser Symmans
W. Fraser Symmans The University of Texas MD Anderson Cancer Center
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Gerald P. Linette
Gerald P. Linette University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Beyond a traditional MD, there are many flexible, online options for those interested in healthcare careers or advancing their qualifications. Nursing offers several entry points, with programs like the fastest lpn program letting aspiring nurses quickly begin their careers as licensed practical nurses.

For licensed nurses looking to specialize, there are pmhnp online programs that allow RNs to become Psychiatric Mental Health Nurse Practitioners, meeting a growing need for mental health professionals.

If you’re interested in the leadership or administrative side of healthcare, consider pursuing a Master of Healthcare Administration. Many of the best online mha programs combine affordability, flexibility, and industry relevance—helping you balance education with work and other commitments.

Cost is a common concern, but it’s worth researching options such as the cheapest online master degree in healthcare administration to find accredited, budget-friendly pathways. These programs can help propel your career forward without incurring significant debt.

Best Scientists Citing Jeffrey S. Ross

Trending Scientists

Recently Published Articles